Table 2. Differences at last measurement between HIV patients who had never received TDF-containing ART(ARTTDF free), those who continuously took a TDF-containing ART (ARTTDF), and those who switched to TDF free (ARTswitched) at Chreso Ministries in Lusaka, Zambia 2011–2013.
ARTTDF free (N = 189) | ARTTDF (N = 856) | ARTswitched (N = 73) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
variable | N | % | mean | sd | N | % | mean | sd | N | % | mean | sd | p-value | |
Sex | women | 124 | 66 | 533 | 62 | 51 | 70 | 0.34a | ||||||
duration of HIV infection [days] | 189 | 100 | 2055 | 803 | 856 | 100 | 1511 | 789 | 73 | 100 | 1776 | 844 | <0.001b | |
duration of ART intake [days] | 189 | 100 | 1918 | 713 | 856 | 100 | 1357 | 791 | 73 | 100 | 1635 | 782 | <0.001b | |
Age [years] | 189 | 100 | 42.2 | 9.1 | 856 | 100 | 41.6 | 8.9 | 73 | 100 | 42.9 | 11.3 | 0.42b | |
BMI [kg/m2] | men | 48 | 74 | 23.3 | 4.2 | 271 | 84 | 23.1 | 4.2 | 18 | 82 | 24.4 | 4.3 | 0.45b |
women | 104 | 84 | 25.3 | 4.9 | 447 | 81 | 25.5 | 5.1 | 40 | 78 | 23.6 | 3.9 | 0.06b | |
mean arterial pressure [mmHg] | 149 | 79 | 100.0 | 15.7 | 711 | 83 | 95.5 | 16.2 | 60 | 82 | 98.1 | 18.7 | 0.006b | |
systolic blood pressure [mmHg] | 149 | 79 | 134.3 | 22.1 | 711 | 83 | 127.1 | 22.1 | 60 | 82 | 131.9 | 26.1 | <0.001b | |
CD4 [ml-1] | 147 | 78 | 455 | 251 | 689 | 80 | 407 | 203 | 41 | 56 | 404 | 247 | 0.05b | |
haemoglobin [g/dl] | 137 | 72 | 13.0 | 1.8 | 609 | 71 | 12.7 | 2.0 | 42 | 58 | 12.0 | 2.1 | 0.02b | |
AST [U/l] | 161 | 85 | 28.6 | 15.2 | 779 | 91 | 31.0 | 18.1 | 53 | 73 | 25.8 | 9.6 | 0.04b | |
ALT [U/l] | 173 | 92 | 28.0 | 25.5 | 821 | 96 | 28.9 | 18.7 | 57 | 78 | 24.7 | 14.8 | 0.28b | |
creatinine [mg/dl] | 189 | 100 | 0.8 | 0.3 | 856 | 100 | 0.8 | 0.3 | 73 | 100 | 1.1 | 0.6 | <0.001b | |
CKD-EPI eGFR [ml/min/1.73m2] | 189 | 100 | 100.8 | 21.4 | 856 | 100 | 101.1 | 21.4 | 73 | 100 | 81.5 | 30.4 | <0.001b | |
eGFR category | 1, 2 | 178 | 94 | 826 | 96 | 52 | 71 | <0.001a | ||||||
3a-5 | 11 | 6 | 30 | 4 | 21 | 29 | ||||||||
Anaemiac | yes | 44 | 32 | 222 | 36 | 20 | 48 | 0.19a | ||||||
no | 93 | 68 | 387 | 64 | 22 | 52 | ||||||||
missing | 52 | 28 | 247 | 29 | 31 | 42 | ||||||||
liver encymes | yes | 4 | 3 | 16 | 2 | 1 | 2 | 0.94a | ||||||
>2•ULNd | no | 157 | 97 | 760 | 98 | 52 | 98 | |||||||
missing | 28 | 15 | 80 | 9 | 20 | 27 | ||||||||
liver encymes | yes | 1 | 1 | 0 | 0 | 0 | 0 | 0.08a | ||||||
>5•ULNe | no | 159 | 99 | 775 | 100 | 53 | 100 | |||||||
missing | 29 | 15 | 81 | 9 | 20 | 27 | ||||||||
systolic blood | <120 mmHg | 40 | 27 | 284 | 40 | 22 | 37 | 0.004a | ||||||
pressure | 120–139 mmHg | 56 | 38 | 250 | 35 | 16 | 27 | |||||||
> = 140 mmHg | 53 | 36 | 177 | 25 | 22 | 38 | ||||||||
missing | 40 | 21 | 145 | 17 | 13 | 18 |
a χ2-test
b ANOVA, two-sided
c Anaemia was defined as Hgb below 13 [g/dl] for men, and below 12 [g/dl] for women.
d Liver disease was defined if at least ALT or AST were twice the upper limit of normal (ULN) of 50 [U/l] for men and 35 [U/l] for women.
e Presence of severe liver disease was assumed if at least ALT or AST were five times higher than the ULN.